跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BEOVU brolucizumab (rbe) 120 mg/mL solution for injection in vial - TGA Drug Approval Details
Approvals
/
TGA
/
BEOVU brolucizumab (rbe) 120 mg/mL solution for injection in vial
Approved
STANDARD
BEOVU brolucizumab (rbe) 120 mg/mL solution for injection in vial
Novartis Pharmaceuticals Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
Dec 9, 2025
Approval ID
2dec3446e78f1d2a
Company
Novartis Pharmaceuticals Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
2dec3446e78f1d2a
Product Name
BEOVU brolucizumab (rbe) 120 mg/mL solution for injection in vial
Artg Id
313680
Artg Name
BEOVU brolucizumab (rbe) 120 mg/mL solution for injection in vial
Sponsor
Novartis Pharmaceuticals Australia Pty Ltd
Company Detail Path
/organization/novartis-pharmaceuticals-australia-pty-ltd
Artg Date
2020-01-16
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Product Information
https://medical-cdn.nocode.com/drug_tga/3d979f1621ac96e1327b2387969928db.pdf
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
Dec 9, 2025
Approval ID
2dec3446e78f1d2a
Type
Standard
Back to TGA Approvals
